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Abstract  This  research  evaluated  the  inter-batch  variability  in  the  identification  and  quality
control of  glucose,  according  to  international  specifications  detailed  in the  guide  CLSI  EP-15.
Type of  qualitative  research,  analytical,  not  experimental,  prospective  cross-sectional  con-
ducted at  the  Department  of  Clinical  Laboratory  at  Polyclinic  ‘‘La  Fe’’  during  January  2015  was
performed.  The  inter-batch  variability  for  glucose  in the semi-automated  biochemical  analyzer
URIT-810  with  liquid  enzyme  glucose-LS  reagent  (GOD-PAP)  Valtek®  batch  140825  was  evalu-
ated. The  calibrators  (CS)  were  the  lot  CS-A:  140  428,  CS-B:  120912  and  CS-C:  131  202.  Data
analysis was  performed  in  SPSS  version  20.0  statistical  analyzer  and  Microsoft  Office  Excel  2010
for Windows.  The  values  found  by  calculating  the  sigma  metric  were:  2 (SE  −0.35),  0 (SE
1.65) −0.9  (SE  −0.75)  to  CS-A,  CS-B  and  CS-C,  respectively  (p < 0.05). Only  CS-A  might  be
able to  improve  their  performance,  although  with  greater  cost.  Sub-optimal  performance  char-
acteristics  by  using  standard  calibrators  show  high  inter-lot  variability,  suggesting  the choice
and search  for  a  new and  better  calibration  method  to  ensure  results  that  contain  no medically
important  errors  affecting  patient  health.
© 2016  Universidad  Auto´noma  de  Nuevo  Leo´n.  Published  by  Masson  Doyma  Me´xico  S.A.  This  is
an open  access  article  under  the CC BY-NC-ND  license  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
Introduction
Glucose  is the main  energetic  biomolecule  for  most  liv-
ing  systems,  responsible  for  maintaining  cellular  functions
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through  glucid  catabolism.  Since  its  isolation  in 1747  by
Andreas  Sigismund,  and the  discovery  of  its  configuration
in  1902  by  Emil  Fisher,  the  function  of  glucose  has  been
explained  and  correlated  with  the development  of diverse
disorders  and homeostatic  mechanisms  for  its control.1
Thus,  glucose  allows  for  the diagnosis  of  several  disorders,
such  as  diabetes  mellitus,  Cushing’s  syndrome,  meningeal
inflammatory  processes,  metabolic  syndrome,  heredofamil-
ial  intracorpuscular  hemolysis,  and  even  enzymopathies,
intolerance  or  improper  carbohydrate  enteric  absorption,
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kidney  diseases,  and  in vitro tests  for  cellular  functional
status  evaluation,  in addition  to  being  used  as  a  preserva-
tion  agent  for  haemocomponents,  among  others.2 Hence,
glucose  is  transcendental  for  diagnosis in  almost  all  clinical
laboratories  areas.
It  is mainly  used for  diagnosing  diabetes  mellitus  (DM),
a  metabolic  disease  which  imposes  a high  economic  and
social  cost  in the world  today,  especially  type  II  DM.
Diagnosis  is  made through  signs and  symptoms  and stim-
uli/response  tests,  such  as the  oral  glucose  tolerance
test  (OGTT),  among  others.3,4 Moreover,  explorations  of
carbohydrate  metabolism  are  employed,  such as  random
glycemias,  fasting  plasmatic  glycemias,  the  glucose  toler-
ance  with corticoids  test  and,  recently,  with  the glycated
hemoglobin  A1C  test,  as  well  as  plasmatic  insulin  level  eval-
uations,  peptide  C and glucagon  dosing,  and glucose  in urine
and  lipid  profiles.5--7
Determined  values  indicate  how  the organism  controls
glucose.  Biochemical  determination  is  generally  performed
with  reducing  methods,  enzymatic  methods  (hexokinase,
glucose-oxidase,  and  glucose-dehydrogenase),  and  commer-
cial  determinations  by  dry  chemistry  for  clinical  diagnosis,
as  well  as  for  in-home  monitoring  and  immunoradiometric
trials.  Enzymatic  methods  in commercial  presentations  are
the  most  utilized,  followed  by  patient  monitoring  by  dry
chemistry,  usually  with  acceptable  sensitivity  ranges  and
error  margins.8 Nevertheless,  glucose  is  one of the metabo-
lites  which  suffers  more  pre-analytic  and analytic  changes,
and  one which  presents  an elevated  biological  intra-  and
inter-individual  variability.  However,  the  reagent  maker
incorporates  internationally-validated  technical  specifica-
tions;  due to  different  factors,  these cannot  be  reproduced
in  the  routine  laboratory,  thus  making  quality  control  under
work  conditions  which  guarantee  the quality  of  their  results
necessary.9,10
Parameters  to  ensure  quality  in clinical  biochemistry,  as
described  by  the  Clinical  Laboratory  Standards  Institute
(CLSI),  include  analytical  methods  and  verification  guides
which  lead  to  a  correct  planning  and choosing  of  qual-
ity  control  rules  for  continuous  monitoring  of  performance
under  work  conditions.  Obtaining  of these  dates  the total
error  of  laboratory  method  (Tea)  is  comparable  to  the  max-
imum  permissible  error  designed  from  different  sources
like  the  Clinical  Laboratory  Improvement  Amendments  1988
(CLIA’88),  biological  variability,  RCPA  regulatory  require-
ments,  etc. Subsequently,  planning  and  method  control  as
well  as  quality  will show continuous  improvement.11
Quality  verification  of  a  method’s  analytical  character-
istics  is  applicable  to  all  kinds  of  laboratories.  In  addition
to  measurable  data  on  the system’s  performance  (inaccu-
racy  and  bias),  quality  requirements  and  real reference
values  are  necessary.12 Quality  requirements  for  glucose  are
diverse,  with  maximum  quantifiable  permissible  error  values
up  to  ±10%  (±6  mg/dl)  in most  sources.5,13
Subsequent  to  the establishment  of  internal  quality
control,  the  same  reagent  lot  should  be  maintained  in  bio-
chemistry  (and  hematology)  for  a  year,  in order  to  control
performance.14 Likewise,  variability  of  the  control  materials
from  lot-to-lot  should  be  minimal.  Since  it  represents  a  small
amount  of  observed  variation,  this  should not  exceed  10%.15
Amongst  the  community,  the circulation  of  lyophilized  con-
trols  is predominant,  which,  unlike  liquid  controls,  present
higher  error  and  stability  and lower  cost, but  require  careful
handling  of volumetric  material,  distilled  water  and recon-
stitution.
Within  the community,  there  are  few  clinical  analysis  lab-
oratories  with  quality systems  in  biochemistry.  Consistent
with  the  evolution  of  laboratories,  most  National  hospi-
tals  and  some private  Health  Centers  in Lima  maintain
internal,  external  and  inter-laboratory  quality  implementa-
tion  without  a  cosmopolitan  reach  in  the  capital.  The  vast
majority  of  new  clinical  laboratories  with  economic  limi-
tations,  interest  of  profit,  or  those  which  are unfamiliar
with  the  clinical  impact  of  results  without  a  quality  system
only  use  ‘‘standard  calibrator’’  controls,  usually  semiauto-
matic  biochemical  analyzers  provided  by  the manufacturer
as  a quality  reference  for  work  performance  evaluation  and
result  reliability.
It is  evident  that  the lack  of  conscience  about  this  subject
and  the ample  uncertainty  produced  in  the  result,  since  the
error  is  not  quantified  or  corrected,  will  be magnified  pro-
gressively  and  become  uncontrollable.  In this  regard,  some
of  the most  commonly  used reagents  in  clinical  chemistry
amongst  the  community  do  not  have the  same  lot  inside  the
kit  (in  other  words,  a  different  lot  for  the  enzymatic  reagent
and  for  the standard  calibrator).  Then,  how  can  the quality
of  the results  be  ensured  in  these conditions?
The  objective  of  this investigation  was  to  assess  inter-
batch  variability  in the determination  and  quality  control
of  glucose,  according  to the  international  specifications
detailed  in  the  CLSI  EP-15-A3  guide.
Method and materials
A qualitative,  analytic,  non-experimental,  prospective
cross-sectional  study  was  conducted  in the Clinical  Labo-
ratory  Department  at  the biochemical  area of  the  ‘‘La  Fe’’
Polyclinic  Health  Care  Center  during January,  2015.  Glucose
inter-batch  variability  was  assessed  according  to  the CLSI
EP15-A3  guide,  highlighting  the usefulness  of ‘‘control  let-
ters’’  (metric  sigma,  power  control  chart  and  Normalized
OPSpecs  chart).12
Sample
On-probabilistic,  sampling  intentionally  by  convenience.
Biochemical  analyzer
In order  to  perform  determinations,  we  used  aURIT-810
Medical  Electronic  (Guangxi,  PR China)  semiautomatic  bio-
chemical  analyzer,  which  was  stabilized  to  220  V,  100  VA.
Reagents
Valtek®Glucose-LS  enzymatic  liquid  reagent  (Valtek  diagno-
sis,  Santiago  de Chile,  Chile)  lot  140825,  with  a storage  range
between  2 and 8 ◦C,  50  ml  bottle,  with  glucose  oxidase-
peroxidase  (GOD-PAP)  enzymatic  colorimetric  method,
modified  based  on  the  publication  by  Trinder  in 1969.16 First
level  calibrator  kit (calibrator  standard  glucose  ‘‘CS’’  (CS-
A))  and  normal  fixed  value  (100  ±  1 mg/dl)  of  lot  140428,  B
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Figure  1 Work  scheme  within  the  glucose  serum  matrix.
and C  calibrators  (CS-B  and  CS-C) of  lot  120912  and  131202,
respectively  (100  ±  1  mg/dl).
Control  reagent
In  order  to  perform  method  verification,  the  kit’s  ‘‘standard
calibrators’’  were  utilized  as  controls  according  to  operative
needs.
Data recollection  technique  and sample  processing
According  to the maker’s  recommendations,  CSs were  sta-
bilized  at  room  temperature  (room  temperature  25  ±  2 ◦C)
for  10  min  before  processing.  The  equipment  stabilized  for
10  min  before  the  analytic  runs. A blank  reagent  was  used
before  the  analysis  verification  from  lot-to-lot.  In  order  to
evaluate  precision,  three  sets  of  measurements  were  made
five  days  in  a  row. For  the  evaluation  of  veracity,  duplicates
of  the  5 days  of the  precision  protocol  of  the 3 control  mate-
rials  for  glucose  were  necessary  (CS-A,  CS-B  and  CS-C).12
Analytic  runs  were  conducted  by  the  institution’s  personnel
under  the  work’s  protocol  specifications.17 Procedures  for
glucose  verification  were  conducted  using the  CLSI  EP-15-
A3  guide,  measured  in standard  deviation  (SD)  and  variance
coefficient  (%VC)  to  asses  bias and  imprecision.  With  the
data  obtained  from  %VC,  bias and  Tea,  the  dot  and opera-
tive  lines  were  determined  to  evaluate  the  performance  of
the  methodology,  demonstrated  in graphics  within  control
letters.  These  determine  the amount  of controls  necessary
for  the  analytical  run,  as  well  as  the  clinical  assay  control
rules.18 The  work  outline  is  shown  in Fig.  1.
Data  analysis  technique
Data  analysis  was  done  using  the  statistical  analyzer  IBM
SPSS,  version  21  (Armonk,  USA)  and  MS Excel  2010  (Red-
mond,  USA)  for  windows.  The  quality  matrix  was  developed
in an  Excel  sheet  showing  SD,  %VC,  Tea,  six  sigma  and  critical
systemic  error  (SDE  or  SE).
Limitations
Several  limitations  ought to  be addressed  before  interpre-
ting  results.
First,  there  may  be failures in the  conservation  or  sta-
bility  of  standard  calibrators,  within  domestic  distribution
by  franchises  or  the  brand’s  commercial  distributors.  These
may  be the  cause  for  erroneous  results.  A second  limitation
is  the  fact  that  we were  not  able  to  compare  the inter-
batch  glucose  variability  results  found  in  this  study  with
those  described  by  Valtek  reagents  for  glucose,  which do
not show  significant  systemic  differences  in accuracy  and
imprecision  when  compared  to  other  commercial  reagents,
obtained  using the BS  series  MINDRAY  auto-analyzer.16 A third
limitation  is  that  the  clinical  biochemistry  laboratory  where
the  study  was  conducted  is  not  accredited  under  the  ISO
15189  norm,  but  it does  have  the technical  and  manage-
rial  requirements  of  the ISO  9001  norm  implemented.  The
fourth  limitation  is  control  sera  VALTROL-N  (code  210-100)
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Table  1  Average  bias%,  %CV,  tea  for  glucose  with  three  CS.
CS-A  CS-B CS-C
bias%  0  10  21
%CV 6  11  12
Teaa 10  10  10
Sigma 2  0 0.9
SE 0.35  −1.65  −0.75
a Quality requirements under CLIA’88.
and  VALTROL-P  (code  210-110)  are used  in the  biochemi-
cal  field  on  a weekly  basis.  Lastly,  not  all  linked  protocols
were  analyzed  with  method  verification  (linearity,  detection
limit,  reference  values,  etc.)11,17.  Despite  these  limitations,
this  research  is  the first  to  describe  verification  processes,
planning  and  quality  control  using  standard  calibrators  such
as  control  sera  in clinical  biochemistry.
Results
Of  the  conducted  research,  the values  found  by  the sigma
metric  calculation  were 2,  0  and  −0.9,  for  CS-A,  CS-B and
CS-C,  respectively.  These  indicate  a  very  poor  performance,
which  cannot  be  controlled  or  maintained  within  the  appli-
cation  of  a statistical  control  (p  < 0.05).19 (Table  1)
Sigma  metric  is  a process  improvement  methodology.
Its  only  goal  is  to  reach  less  than  one defect  per  million
(99.9997%  successes).  Although  quality  requirements  are
different  for  each  magnitude,  these  unify  with  six sigma
in  order  to compare  methods  with  a  single  value.20 In  this
sense,  we  are  able  to express  values  and  know  statistical
control  strategies  based  on sigma,  as  shown  in Fig.  2 as  an
example.
Other  control  letters  are  operative  specification  graphics
(OPSpecs)  and power  control  chart.  Power  control  chart
represent  the most  powerful  graphic  because  of  the vast
amount  of data  which  can  be obtained  from  them  during
quality  planning.  These  requires  SE  calculations,  based
on  the  method’s  maximum  permissible  error,  which  should
not  be  more  than  the quality requirements  (up  to 90%
of  quality  assurance),  which  equals  the statistical  value
of  1.65  standard  deviations.21 These  functions  present
the information  about  the  performance  of  a rejection
probability  graphic  control  rule  versus  the analytic  error
measures,  as  shown  in  Fig.  3.
Every  one  of the cases  underwent  2  control  levels  for
every  analytical  run (n  = 2).  Choosing  one  control  rule  for
every  analyte,  there  are  fewer  alarms  in internal  control,
thus  freeing  the analytical  run with  a good  chance  of  error
detection  and  a  low  probability  of  rejecting  good  runs.  Every
letter  begins  with  the choice  of  control  rules,  according  to
each  case  (mono-rules  or  multi-rules)  which  evaluate  and
control  immeasurable  systemic  and  random  mistakes.
Discussion
Performance  characteristics  were not  optimal  with  the use
of  standard  calibrators  for  glucose  determination,  accord-
ing  to  the sigma  metric evaluation  (Table  1).  These  deficient
performances  (sigma  <  3)  suggest  a choice  and  search  for  a
new  and  improved  calibration  method  which  improves  pre-
cision,  since  there  is  no  minimum  quality  control  under  the
studied  conditions.  The  analysis  of  results  with  statistical
control  strategy  charts  based  on  sigma  metrics  proves  that
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Figure  2  Sigma  metric  for  glucose  CS-A.  The  deficient  performances  shown  not  optimal  quality  control  process  with  calibrator
standard glucose,  none  of  them  quality  stimations  (National  Test  Quality,  National  Method  Quality  and  Local Method  Quality)  provides
a robusteness  with  CS for  glucose  control.
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Figure  3  Power  control  chart  for  glucose  CS-A.  Show  that  even  though  with  10%  of  probability  for  rejection  be able  establish  a
correct planning  and  choosing  of quality  control  rules  with  statistical  control  chart.
analytical  quality  control  management  with  standard  cal-
ibrators  provided  by  the manufacturer  are  not enough  to
ensure  results  free  of  medically  significant  errors  affect-
ing  the  health  of  the  patient.  Moreover,  statistics  show  the
specific  concentration  test  performance  in work  conditions
inherent  to the  mentioned  laboratory.22
The  vast majority  of  clinical  chemistry  laboratories  in
Lima,  which  use  manual  or  semiautomatic  methodologies,
present  a  high  degree  of  inaccuracy  in glucose  and choles-
terol  determinations,  highlighting  not  only the poor  quality
of  lab  results,  but  also  the need  for  dynamic  and  efficient
controls  which  ensure  quality  in processes.23 By  not using
Good  Clinical  Laboratory  Practices,  the  error  is  not  quan-
tified,  thus  uncertainty  in  the  result  creates  a bad  clinical
diagnosis.  It is  worth  noting  that  quality  is  not  a common
characteristic  amongst  biochemical  laboratories  in Lima.  A
contrario  sensu, with  the development  and  normalization  of
clinical  medicine,  doctors  and  patients  are expecting  high
quality  results,  which  is a  challenge  for  all  laboratories  in
the  community.
Results  provided  during  the calibrator’s  analytical  run
should  be  truthful  and  precise  in order  to  certify  that  routine
analytical  determinations  ensure a minimum  quality  and  a
correct  clinical  interpretation,  in addition  to  being  useful
for  their  inter-laboratory  comparability.22,23
OPSpecs’  statistical  control  letters  as  well,  as  power
control  chart,  describe  the acceptable  imprecision  and
inaccuracy  for  a method  and  quality  control  necessary  to
supervise  performance,  as  well  as  the  test  performance
under  stable  conditions,  and  warn  if there  are any  changes
that  may  affect  the  report.  The  goal  is to  obtain  <90%  prob-
ability  of  error  detection  (Ped  or  AQA)  and  less  than  5%
probability  of  false  rejection  (Pfr),  with  an N (amount  of
controls  being  analyzed)  as low as  possible  and  in  a single
analytical  run.24 In  the  example  shown  in Fig. 3, none of
the  rules  is  eligible,  with  two  controls  per  analytical  run.
Through  the  use  of control  materials  ‘‘CS’’  and  a proper
statistical  management,  we  are able  to  prove  that  no  rule
or  control  is  useful in  the  verification  of the method.25,26,27
In the  same  manner,  the error  in Valtek’s  critical
glucose-LS  levels  were  estimated.  The  systemic  error  is  the
difference  between  the  conventionally  truthful  value and
the  median  value of  a number  of determinations  which
are  experimentally  measured.  Within  this  investigation,
we  were  able  to  find  a 0%,  10%  and  20%  of  bias  for  CS-
A,  CS-B  and  CS-C,  respectively.  On the  other  hand,  the
systemic  error,  that  is  to  say  the  resultant  precision  of
the  approximation’s  repeated  measured  values,  were  6%,
11%  and  12%  of  CS-A,  CS-B  and CS-C,  respectively.  These
continuous  quantitative  variables,  when  expressed  graph-
ically,  show  the wide  inter-batch  variability  and  error  for
glucose.  Of  these,  only lot  140428  (CS-A)  could  be  capa-
ble  of  improving  its  performance  of being  indispensable
for  analysis  in the  laboratory,  in other  words,  capa-
ble  of recognizing,  monitoring,  minimizing  and  correcting
errors,  although  it  would  be costly  to maintain  it  within
quality.14,15,17
The  causes  of  this  variability  could be  linked  to  different
motives,  which  it  is  not  an  objective  of this investigation  to
describe.  But it  is  to  consider  whether  or  not  some  factors
are  directly  interfering,  such  the matrix  type,  signal  varia-
tion  between  equipment,  lack  of  noise  control,  CS  behavior
in  work  conditions,  measured  commutability,  transportation
and  control  storage  and  lack  of preventive  maintenance,
to  name  a few.  In  consequence,  full  routine  monitoring  is
ineludible.
Glucose  concentration  is  very  important  for  endocri-
nologists,  diabetologists  and  diabetic  patients,  even  when
dysglycemic  or  apparently  healthy,  particularly  when  the
concentration  is  close  to  the upper  limit  of  the reference
interval  (±10%  or  6.1  mmol/L).28 The  concerning  prevalence
of  diabetes  and  prediabetes  suggests  the immediate  prioriti-
zation  of health  care  in order  to  avoid  future  complications.
Diagnosis  by stimuli-response  and/or  explorations  of  the
carbohydrate  metabolism  ought to  be evaluated  for  all
phenomena  which may  intervene  during  every  analysis  and
generate  non-quantifiable  errors,  which  will  not  ensure
quality  in  results.3,29
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Conclusions
In  this  investigation,  the measure  of  standard  glucose
calibrators  was  performed  in order  to  prove  inter-batch
variability  and  the  application  of  control  letters,  follow-
ing  evaluation  procedures  recommended  by  the CLSI  EP15
guide.  Total  error  was  identified  and  quality  control  neces-
sary  to  control  the  method  performance  was  evaluated.
The  wide  inter-batch  variety works  against  result  repro-
ducibility  and  quality,  hence  we  must  opt  for  a different
control  material  for  quality  monitoring  in glucose-LS  deter-
mination  with  Valtek® reagents.  Quality  planning  helps
clinical  analysis  laboratories  which  don’t  quantify  errors  or
guarantee  a trustworthy  diagnosis  face quality  challenges.
However,  the problem  with  variability  and  quality  control
estimations  is  that  most  laboratory  users  are not familiarized
with  the  concepts  and the measuring  process  is  still  hier-
archically  restrained  to  reference  methods,  which  ensure
process  traceability,  but  are not accessible  for  every  clinical
laboratory  nationwide.
It  is  not  a  problem  for  our  method  to  work  with  a  cer-
tain  degree  of  error.  The  problem  is for this error  to be
greater  than  the maximum  permissible  amount,  according
to  the  method’s  quality  specifications.  In this  sense,  quality
of  results  is  not  guaranteed  by using  only  standard  calibra-
tors  provided  by  the manufacturer;  this  evaluation  should
be  the  starting  point  to  develop  quality  processes.
Analytical  chemistry  should not only equilibrate  a col-
lection  of  data  and  methods,  but  obtain  representative
samples,  optimize  methods  and interference  management
and  guarantee  quality  of  data.  We  hope  this  investigation
is  able  to  promote  the use  of  optimal  control  materials  for
correct  planning  and  quality  control  in  clinical  analysis  lab-
oratories.
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